Recipharm invests in its pMDI valves production capacity
Recipharm, a leading contract development and manufacturing organisation (CDMO), has announced an investment into its King’s Lynn, UK facility, which specialises in inhalation and nasal device development and manufacturing, under the brand Bespak by Recipharm. The investment will expand the company’s pressurised metered dose inhaler (pMDI) valves production capacity and is set to come on stream in late 2021, further reinforcing the facility’s already robust operations. The investment follows the acquisition of Consort Medical earlier this year and the subsequent launch of Recipharm’